Media About Us


  • 02 February 2018

    Syndax entered a clinicial trial collaboration with AstraZeneca

    Syndax entered a clinicial trial collaboration with AstraZeneca

    GMP News

    Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced a new clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca’s durvalumab.

  • 02 February 2018

    AstraZeneca, Syndax ally to test PD-L1 drug and CSF1R inhibitor in solid tumor patients

    AstraZeneca, Syndax ally to test PD-L1 drug and CSF1R inhibitor in solid tumor patients

    Nick Paul Taylor / FierceBiotech

    AstraZeneca and Syndax have teamed up to test immune checkpoint inhibitor Imfinzi in combination with CSF1R inhibitor SNDX-6352. Syndax is set to put the cocktail through a phase 1b solid tumor trial to equip both companies to sponsor midphase trials to demonstrate its safety and efficacy.

  • 23 January 2018

    Blockchain as a technology goes far beyond cryptocurrency application. Interview with Maxim Gorbachev, Managing Partner at RMI Partners

    Blockchain as a technology goes far beyond cryptocurrency application. Interview with Maxim Gorbachev, Managing Partner at RMI Partners

    #WBSMoscow

    As the blockchain revolution gains momentum around the world, Trescon had the opportunity to interview Maxim Gorbachev, a Managing Partner at RMI Partners, on the evolving nature of blockchain. RMI Partners is a venture capital company established in 2012, with a strategic focus on investments supporting the development of innovative biopharmaceutical products and medical technologies.

  • 19 January 2018

    Start Up Spotlight: OCON Medical Bets On A New 3D Copper Contraceptive Device

    Start Up Spotlight: OCON Medical Bets On A New 3D Copper Contraceptive Device

    Catherine Longworth / MedTech Insight

    Israeli start up OCON Medical is blazing a trail in the field of women's health with a new hormone-free contraceptive device. The company's IUB – intrauterine ball consists of copper pearls that prevent pregnancy locally within the uterus for five years.

  • 12 January 2018

    Corneal inlays need a boost from eye care providers

    Corneal inlays need a boost from eye care providers

    Healio

    The Raindrop corneal inlay from ReVision Optics and the AcuFocus Kamra corneal inlay have been implanted in thousands of eyes. Ninety-five percent of patients with these devices report being quite satisfied, according to surveys, and virtually all implanting surgeons report they would recommend the procedures to their colleagues.

  • 11 January 2018

    Genentech, Syndax expand HDAC-PD-L1 combination pact

    Genentech, Syndax expand HDAC-PD-L1 combination pact

    Nick Paul Taylor / FierceBiotech

    Genentech and Syndax have expanded their exploration of the effects of combining HDAC and PD-L1 inhibitors. The new agreement clears the Roche subsidiary to test its Tecentriq in combination with Syndax’s entinostat in a subset of breast cancer patients.

  • 11 December 2017

    An Epic quest to detect cancer

    An Epic quest to detect cancer

    Bradley J. Fikes / The San-Diego Union Tribune

    Finding needles in a haystack is the life-and-death job of San Diego’s Epic Sciences. The needles are extremely rare cancer cells that hide among the millions of normal cells in the blood of cancer patients.

  • 23 October 2017

    Contract R&D market is developing in Russia

    Contract R&D market is developing in Russia

    GMP News

    NovaMedica has launched in Moscow its R&D Center for development of new drug products. The Center is going to become attractive R&D site for customized developments and contract manufacturing.

  • 23 October 2017

    Russian pharmaceutical map has a new point of convergence

    Russian pharmaceutical map has a new point of convergence

    GMP News

    An interesting international pharmaceutical project has started in Russia. This project is a result of a convergence of interests of Rusnano, Russian state investment corporation, Domain Associates, an American venture capital foundation, and Pfizer, an American pharmaceutical corporation.  

  • 08 September 2017

    New 30-minute STI test allows just one clinic trip

    New 30-minute STI test allows just one clinic trip

    Helen Clark / Gears of Biz

    A new speedy test will mean that for the first time ever patients with common sexually-transmitted infections will be able to get their diagnosis and treatment in one clinical visit. The test works by placing a swab or a small amount of urine into a test cartridge, which is then inserted into the diagnostic machine, which has been designed by innovation firm Atlas Genetics Ltd.